Journal

Liquid biopsy in bladder cancer: State of the art and future perspectives

Read time: 1 mins

Published:1st Feb 2022

Author: Crocetto F, Barone B, Ferro M, Busetto GM, La Civita E, Buonerba C et al.

Source: Critical Reviews in Oncology/Hematology

Availability: Pay for access, or by subscription

Ref.:Crit Rev Oncol Hematol. 2022 Feb;170:103577.

DOI:10.1016/j.critrevonc.2022.103577

Liquid biopsy in bladder cancer: State of the art and future perspectives

Bladder cancer is the most common malignancy of the urinary tract. Cystoscopy represents the gold standard in the diagnosis of suspicious bladder lesions. However, the procedure is invasive and burdened by pain, discomfort and infective complications. Cytology, which represents an alternative diagnostic possibility is limited by poor sensitivity. Considering the limitations of both procedures, and the necessity to perform multiple evaluations in patients who are in follow-up for bladder cancer, an improved non-invasive methodology is required in the clinical management of this disease. Liquid biopsy, e.g. the detection of clinical biomarkers in urine, represent a promising novel and non-invasive approach that could overcome those limitations and be integrated into the current clinical practice. The aim of this review is to summarize the state of the art of this approach and the latest novelties regarding detection, prognosis and surveillance of bladder cancer.

Read abstract on library site Access full article